Druga | Ki for 5-HT2Ab | Ki for 5-HT2Cb | DD ED50c | Potency Relative to LSD (Rat DD) | Human Dosed | Potency Relative to LSD (Human) |
---|---|---|---|---|---|---|
nM | μM/kg | mg | ||||
EthLAD | — | — | 0.02 | 185 | 0.04–0.15 | 140 |
AllyLAD | — | — | 0.013 | 285 | 0.08–0.16 | 110 |
LSD | 2–4 | 3–6 | 0.037 | 100 | 0.06–0.20 | 100 |
ProLAD | — | — | 0.037 | 100 | 0.10–0.20 | 90 |
DOB | 0.6 | 1.3 | 1.06 | 2.3 | 1–3 | 7 |
DOI | 0.7 | 2.4 | 0.28 | 9.2 | 1.5–3 | 6 |
DOM | 19 | ND | 0.89 | 3.3 | 3–10 | 2 |
Psilocin | 15–25 | 10 | 1.0 | 2.6 | 10–15 | 1 |
DMCPA | ND | ND | 0.66 | 4.5 | 15–20 | 0.7 |
MEM | 73 | 124 | 12 | 0.2 | 20–50 | 0.4 |
MMDA-2 | ND | ND | 7 | 0.4 | 25–50 | 0.4 |
Mescaline | 550 | 300 | 34 | 0.08 | 200–400 | 0.04 |
AllyLAD, N-allyl-N(6)-norLSD; DD, drug discrimination; DMCPA, (±)-trans-2,5-dimethoxy-4-methylphenylcyclopropylamine; EthLAD, N-ethyl-N(6)-norLSD; MEM, (±)-2,5-dimethoxy-4-ethoxyamphetamine; MMDA-2, (±)-2-methoxy-4,5-methylenedioxyamphetamine; ProLAD, N-n-propyl-N(6)-norLSD.
↵a Drug abbreviations are from Shulgin and Shulgin (1991, 1997).
↵b Affinity of phenethylamines in cloned receptors taken from Nelson et al. (1999); mescaline affinity is from Monte et al. (1997).
↵c Drug discrimination data from Blair et al. (2000), Hoffman and Nichols (1985), Monte et al. (1997), and Nichols et al. (1984a,b, 1986, 1991).
↵dAveraged dose range from Shulgin & Shulgin (1991, 1997) (LSD = 100).